S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Is Buying an Aged Corporation a Good Idea?
Is This The End of Capitalism? (Ad)
MarketBeat Week in Review – 1/23- 1/27
Lots of sound and fury on US debt, but not a crisis — yet
Is This The End of Capitalism? (Ad)
Italy's premier visits Libya for talks on energy, migration
Japan firm opens whale meat vending machines to push sales
Is This The End of Capitalism? (Ad)
Italy, Libya sign $8B gas deal as PM Meloni visits Tripoli
Online system to seek asylum in US is quickly overwhelmed
NYSE:ADCT

ADC Therapeutics - ADCT News Today

$5.05
+0.33 (+6.99%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$4.64
$5.07
50-Day Range
$2.87
$5.20
52-Week Range
$2.69
$17.89
Volume
346,779 shs
Average Volume
691,223 shs
Market Capitalization
$387.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$11.50
Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.



ADCT Media Mentions By Week

ADCT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ADCT
News Sentiment

0.00

0.70

Average
Medical
News Sentiment

ADCT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ADCT Articles
This Week

8

2

ADCT Articles
Average Week

SourceHeadline
marketbeat.com logoADC Therapeutics SA (NYSE:ADCT) Receives Average Recommendation of "Moderate Buy" from Brokerages
marketbeat.com - January 25 at 5:09 AM
MarketBeat logoADC Therapeutics SA (NYSE:ADCT) Receives $11.50 Average Target Price from Analysts
americanbankingnews.com - January 28 at 1:44 AM
MarketBeat logoMorgan Stanley Trims ADC Therapeutics (NYSE:ADCT) Target Price to $5.00
americanbankingnews.com - January 27 at 5:50 AM
MarketBeat logoADC Therapeutics SA (NYSE:ADCT) Given Average Rating of "Moderate Buy" by Brokerages
americanbankingnews.com - January 25 at 5:14 AM
markets.businessinsider.com logoMorgan Stanley Reaffirms Their Hold Rating on ADC Therapeutics (ADCT)
markets.businessinsider.com - January 24 at 1:50 PM
msn.com logoThe Latest Analyst Ratings for ADC Therapeutics
msn.com - January 24 at 1:50 PM
markets.businessinsider.com logoCan ADC Therapeutics Strike Gold With Lymphoma Drug Zynlonta?
markets.businessinsider.com - January 18 at 8:22 AM
finance.yahoo.com logoWall Street Analysts Think ADC Therapeutics SA (ADCT) Could Surge 174.2%: Read This Before Placing a Bet
finance.yahoo.com - January 16 at 1:37 PM
nasdaq.com logoADC Therapeutics Uptrend Continues
nasdaq.com - January 14 at 3:22 PM
seekingalpha.com logoAstraZeneca And Daiichi Sankyo's Zauberkugel (Magic Bullet)
seekingalpha.com - January 6 at 2:26 PM
finanznachrichten.de logoPharmaVentures advises IntoCell on Development and License Option Agreement with ADC Therapeutics
finanznachrichten.de - January 5 at 8:56 AM
msn.com logoIntoCell enters development and license option agreement with ADC Therapeutics
msn.com - January 5 at 8:56 AM
msn.com logo4 Analysts Have This to Say About ADC Therapeutics
msn.com - January 4 at 9:17 AM
finance.yahoo.com logoADC Therapeutics to Participate in the 41st Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 4 at 9:17 AM
finance.yahoo.com logoADC Therapeutics Appoints Mohamed Zaki as Chief Medical Officer
finance.yahoo.com - January 3 at 6:48 PM
finance.yahoo.com logoADC Therapeutics and Sobi Announce European Commission Approval of ZYNLONTA® (loncastuximab tesirine) for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
finance.yahoo.com - December 21 at 10:15 AM
finance.yahoo.com logoADC Therapeutics Appoints Jose Carmona as Chief Financial Officer
finance.yahoo.com - December 19 at 12:08 PM
finance.yahoo.com logoFREENOME PRESENTS RESEARCH HIGHLIGHTING THE PROMISE OF IDENTIFYING DRUG-RESPONSE BIOMARKERS FOR DLBCL PATIENTS
finance.yahoo.com - December 12 at 1:03 PM
seekingalpha.com logoADC Therapeutics: Running Through A Stretch Of Bad Luck
seekingalpha.com - November 30 at 10:01 AM
nz.finance.yahoo.com logoBiocytogen Enters into Antibody Agreement with ADC Therapeutics
nz.finance.yahoo.com - November 27 at 7:15 PM
msn.com logoBenzinga's Top Ratings Upgrades, Downgrades For November 9, 2022
msn.com - November 9 at 11:24 AM
seekingalpha.com logoADC Therapeutics SA (ADCT) Q3 2022 Earnings Call Transcript
seekingalpha.com - November 9 at 1:10 AM
finance.yahoo.com logoADC Therapeutics Announces Abstracts Accepted for Presentation at the 64th ASH Annual Meeting
finance.yahoo.com - November 3 at 11:09 AM
finance.yahoo.com logoIGM Biosciences and ADC Therapeutics Announce Clinical Collaboration Agreement to Evaluate Imvotamab (IGM-2323) in Combination with ZYNLONTA® in Patients with Relapsed or Refractory B Cell Non-Hodgkin’s Lymphoma
finance.yahoo.com - November 2 at 7:43 PM
finance.yahoo.com logoADC Therapeutics Appoints Kristen Harrington-Smith as Chief Commercial Officer and Peter Graham as Chief Legal Officer
finance.yahoo.com - November 1 at 8:29 AM
finance.yahoo.com logoADC Therapeutics to Host Third Quarter 2022 Financial Results Conference Call on November 8, 2022
finance.yahoo.com - October 31 at 10:18 AM
finance.yahoo.com logoDown 27.9% in 4 Weeks, Here's Why You Should You Buy the Dip in ADC Therapeutics SA (ADCT)
finance.yahoo.com - October 12 at 1:39 PM
finance.yahoo.com logoDown 28.5% in 4 Weeks, Here's Why ADC Therapeutics SA (ADCT) Looks Ripe for a Turnaround
finance.yahoo.com - October 11 at 12:37 PM
finance.yahoo.com logoADC Therapeutics Announces Abstracts to be Presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022)
finance.yahoo.com - September 21 at 7:16 PM
finance.yahoo.com logoADC Therapeutics and Sobi Announce ZYNLONTA® (loncastuximab tesirine) Receives Positive CHMP Opinion in Europe for the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
finance.yahoo.com - September 16 at 8:59 AM
benzinga.com logoBronstein, Gewirtz & Grossman, LLC Notifies Shareholders of ADC Therapeutics SA (ADCT) Investigation
benzinga.com - September 15 at 5:55 PM
apnews.com logoINVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
apnews.com - September 14 at 4:52 PM
apnews.com logoINVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
apnews.com - September 14 at 4:52 PM
apnews.com logoINVESTIGATION ALERT: The Schall Law Firm Encourages Investors in ADC Therapeutics SA with Losses of $100,000 to Contact the Firm
apnews.com - September 14 at 1:15 AM
msn.com logoWhere ADC Therapeutics Stands With Analysts
msn.com - September 9 at 4:44 PM
markets.businessinsider.com logoExpert Ratings for ADC Therapeutics
markets.businessinsider.com - September 9 at 4:44 PM
finance.yahoo.com logoADC Therapeutics to Participate in Morgan Stanley’s 20th Annual Global Healthcare Conference
finance.yahoo.com - September 6 at 10:11 AM
finance.yahoo.com logoADC Therapeutics SA (ADCT) Q2 2022 Earnings Call Transcript
finance.yahoo.com - August 10 at 3:17 AM
seekingalpha.com logoADC Therapeutics SA (ADCT) CEO Ameet Mallik on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 9 at 5:16 PM
finance.yahoo.com logoADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates
finance.yahoo.com - August 9 at 5:16 PM
finanznachrichten.de logoADC Therapeutics SA: ADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
finanznachrichten.de - August 9 at 8:58 AM
finance.yahoo.com logoADC Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
finance.yahoo.com - August 9 at 8:58 AM
msn.com logoEarnings Outlook For ADC Therapeutics
msn.com - August 8 at 5:57 PM
finance.yahoo.com logoIntercept Pharmaceuticals (ICPT) Reports Q2 Loss, Beats Revenue Estimates (Revised)
finance.yahoo.com - August 5 at 8:11 AM
finance.yahoo.com logoADC Therapeutics to Host Second Quarter 2022 Financial Results Conference Call on August 9, 2022
finance.yahoo.com - August 2 at 7:53 AM
finance.yahoo.com logoEarnings Preview: Moderna (MRNA) Q2 Earnings Expected to Decline
finance.yahoo.com - July 27 at 2:27 PM
finance.yahoo.com logoADC Therapeutics Doses First Patient in Phase 1b Clinical Trial of ADCT-601 Targeting AXL as a Single Agent and in Combination with Gemcitabine in Advanced Solid Tumors
finance.yahoo.com - July 27 at 9:26 AM
finance.yahoo.com logoADC Therapeutics SA (ADCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
finance.yahoo.com - July 26 at 1:25 PM
finance.yahoo.com logoCentene (CNC) Gears Up for Q2 Earnings: What Lies Ahead?
finance.yahoo.com - July 25 at 5:22 PM
finance.yahoo.com logoADC Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of ZYNLONTA® (loncastuximab tesirine-lpyl) in Combination with Rituximab in First-Line Diffuse Large B-Cell Lymphoma
finance.yahoo.com - July 20 at 10:12 AM
finance.yahoo.com logoAnalyst Forecasts For ADC Therapeutics SA (NYSE:ADCT) Are Surging Higher
finance.yahoo.com - July 16 at 8:49 AM
Get ADC Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ADCT and its competitors with MarketBeat's FREE daily newsletter.

This page (NYSE:ADCT) was last updated on 1/28/2023 by MarketBeat.com Staff